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Study Objectives: The aim of this study was to test the efficacy of a fully automated Internet-
delivered CBTi (ICBTi) 18 months after the intervention period on sleep, daytime 
functioning, and beliefs about sleep for adults with chronic insomnia. 
Methods: Participants in this study had participated in a RCT comparing the efficacy of 
unguided ICBTi with web-based patient education. Participants who had received ICBTi 
(N=95) completed online questionnaires and online sleep diaries 18 months after the 
intervention period. We used linear mixed models to study changes from baseline to post-
assessment and to 18-month FU, and a separate mixed models analysis to study changes from 
post-assessment to 18-month FU. 
Results: Mean age of the participants was 45.5 years (SD=12.6) and 64% were females. 
Sixty-six participants (70%) completed the 18-month follow-up (FU) assessment. There were 
significant improvements from baseline to 18-month FU on the Insomnia Severity Index (ISI) 
(Cohen d = 2.04 [95%CI, 1.66-2.42]) and the Bergen Insomnia Scale (BIS) (d = 1.64 [95%CI, 
1.30-1.98]), levels of daytime fatigue (d = 0.85 [95%CI, 0.59-1.11]), psychological distress (d 
= 0.51 [95%CI, 0.29-0.73]), and beliefs about sleep (d = 1.44 [95%CI, 1.15-1.73]). Moderate 
to large effect size improvements were also shown on the diary-derived sleep variables. All 
improvements from baseline to post-assessment were essentially maintained to 18-month FU. 
Conclusions: Unguided ICBTi appear to have sustained effects on sleep, daytime functioning, 
and beliefs about sleep up to 18-months after the intervention period.  






a) Internet-delivered Cognitive Behavioral Therapy for Insomnia (ICBTi) is efficacious 
as treatment for chronic insomnia. However, the long-term effectiveness of such 
treatment on sleep and daytime symptoms has received little attention in previous 
research. 
b) We investigated whether improvements attained during ICBTi on sleep and daytime 
functioning were maintained 18 months after the intervention period.  
c) ICBTi led to improved sleep and reduced symptoms of fatigue and psychological 
distress 18 months after the intervention period. These results add to the growing 
evidence verifying the efficacy of sustained improvements after self-guided Internet-














A recent meta-analysis established the efficacy of both guided and unguided ICBTi 
and reported significant and robust effects on insomnia severity and on several sleep diary 
outcomes.1 It was concluded that the effects, which in terms of effect sizes (Hedges’s g) 
ranged from 0.21 to 1.09, were comparable to those of in-person delivered CBTi.1 The meta-
analysis further showed that the effects of ICBTi were maintained for insomnia severity and 
sleep quality at follow-up assessments (up to 48 weeks). However, for other sleep diary 
characteristics (i.e., sleep onset latency [SOL], wake after sleep onset [WASO], and total 
sleep time [TST]) maintenance of treatment effects was less consistently found. The authors 
recommended that future research should now focus on the long-term efficacy of ICBTi.1 
Three previous trials have examined the long-term outcomes of unguided ICBTi. 
Lancee et al.2 studied treatment gains of ICBTi 48 weeks after treatment completion, and 
found sustained effects. However, the design of that study intended to investigate whether the 
same self-help treatment given online or by paper-and-pencil material produced differential 
results. Due to this they needed to keep the two treatments as similar as possible resulting in 
significant restrictions to the extent interactive and personalized treatment elements were 
offered in the online treatment compared to other ICBTi-programs (e.g.3,4). Ritterband et al.4 
conducted a study comparing ICBTi to a control group and included a one-year follow-up 
assessment. Results demonstrated superior effects of ICBTi on insomnia severity and on sleep 
diary outcomes. That paper, however, did not report the effects of the treatment on other 
outcome measures than sleep, such as daytime fatigue and psychological wellbeing, which 
often are reported consequences of insomnia.5 Using the same ICBTi intervention as 
Ritterband et al.4 (i.e. SHUTi [Sleep Healthy Using the Internet™]), Batterham et al.6 
investigated whether the efficacy of ICBT-I on depressive symptoms and insomnia severity 
were sustained over 18 months compared to a control group. They found symptoms of 
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depression, anxiety and insomnia decreased significantly after the intervention period and 
remained significantly lower compared to the control group for >18 months.6 Notably, the 
between group effect sizes on insomnia severity in that study reduced from 1.27 after the 
intervention period to 0.55 at 18 months follow up (FU) assessment.6 This may suggest an 
increase in sleep problems for the intervention group after the intervention period (or an 
improvement in the control group), but the power calculations are also likely influenced by 
the fact that only 19% of participants completed the 18-month assessment in that study. This 
level of attrition also makes the generality of the results on the long-term effects in that study 
somewhat uncertain. 
In the present study, we report long-term results (18-months FU) from a randomized 
controlled trial comparing unguided ICBTi (SHUTi™) with web-based patient education. In 
previous publications we have demonstrated that the SHUTi-intervention was superior to the 
patient education (control condition) in terms of improving sleep, daytime functioning, and 
psychological wellbeing after the intervention period and that the treatment gains were 
relatively well maintained at 6-month follow-up.7,8 The aim of the present study is to examine 
whether the observed improvements in sleep and daytime functioning from baseline to after 
the intervention period are maintained at 18 months FU in the experimental group. 
METHODS 
Subjects and procedure 
The participants in this study had participated in a randomized controlled trial comparing 
the effects of unguided ICBTi (n = 95) to web-based patient education (n = 86).7,8 Those who 
were randomized to receive unguided ICBTi, were invited to complete another set of online 
questionnaires and 10 days of sleep diaries 18 months following the intervention period (see 
consort diagram in Figure 1). Those who participated in the patient education control group 
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were given access to ICBTi after post-assessment, and thus could not be included in the 18-
month FU study. 
The inclusion procedure is detailed in a previous study7 and is therefore only briefly 
described here: Recruitment took place between November 2013 and March 2014. Eligible 
candidates were screened sequentially by a set of online screening questions, followed by a 
15-minute telephone interview performed by a clinician. The online screening questionnaire 
was anonymous and noncommittal, where candidates received automated feedback based on 
their answers. Eligible candidates were encouraged to contact the research team through a 
dedicated e-mail if they wanted to be evaluated further for eligibility through a telephone 
interview. Candidates had to be 18 years or older, be fluent in Norwegian, have Internet 
access, and report sleep difficulties according to the DSM-IV-TR9 criteria for insomnia 
(difficulty initiating sleep, difficulty maintaining sleep, and/or early morning awakenings; in 
addition to daytime impairment due to sleep disturbance) 3 or more nights per week and for at 
least 3 months. Candidates were ineligible if they reported working night shifts, if they had 
another known sleep disorder such as obstructive sleep apnea, hypersomnia, narcolepsy, or 
were diagnosed with severe mental illness (e.g., current major depressive disorder, bipolar 
disorder, schizophrenic disorder). A single item question was used to assess sleep apnea in the 
online screening questionnaire: “During the last four weeks, how often have you experienced 
interrupted breathing during your sleep?” Those who answered “usually” or “always” were 
excluded from the study. Depression was assessed in the online screening questionnaire using 
MADRS-S,10 in which >19 points indicates moderate/severe depression and was set as 
exclusion criterion. Further assessment of the candidates’ sleep problems and mental health 
was done during the telephone interview; where those who reported being diagnosed with 
hypersomnia, narcolepsy, a major depressive disorder, bipolar disorder, or schizophrenic 
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disorder were excluded. Use of hypnotics for sleep problems or other medications was not an 
exclusion criterion.  
Treatment 
The ICBTi program (SHUTi™)11 consists of 6 online sessions designed to be completed 
weekly during a 9 week period. The weekly sessions covered the basic topics of CBTi,12 
including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and 
relapse prevention. The treatment recommendations provided by the program are personalized 
for patients based on each individuals’ input in the program throughout the treatment (for 
more details about the SHUTi program, see Thorndike et al.13). After the 9-week treatment 
period, participants were re-assessed with online questionnaires and online sleep diaries (10 
diaries in a 14-day period). Participants were contacted at 6-month FU,7,8 and in terms of the 
current study, also at 18-month FU and asked to complete the same assessment 
(questionnaires and 10 days of sleep diaries).  
Ethics 
The study was approved by the Regional Committee for Medical and Health Research 
Ethics in SouthEast Norway (2012/1934 REK, SouthEast B). Informed consent was provided 
and participants were compensated NOK 500 (approximately USD 60) for completing the 18-
month FU assessment. ClinicalTrials.gov Identifier: NCT02261272. 
Instruments 
Insomnia Severity Index (ISI) is a brief self-report instrument measuring the patient's 
perception of his or her insomnia. It contains seven questions that target the participants’ 
symptoms and consequences of insomnia, and the level of distress they experience in relation 
to these difficulties. Each item is rated on a 0–4 Likert scale, hence the composite scores 
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range from 0 to 28, where higher scores suggest more severe insomnia. The ISI is a reliable 
self-report measure and has demonstrated adequate sensitivity to changes in response to 
treatment, where participants are considered responders to treatment if the ISI score decreases 
by 8 or more points.14,15 An ISI score of less than 8 is the most widely used remission 
criterion.16 The instrument has previously demonstrated excellent internal consistency.15 
Cronbach alphas at pre-, post-, and 18-month FU in the present study were .51, .73, and .87, 
respectively. 
Bergen Insomnia Scale (BIS)17 comprises six items that assesses symptoms of insomnia 
based on the American Psychiatric Association (APA)'s Diagnostic and Statistical Manual of 
Mental Disorders-IV-TR.18 Subjects are asked to indicate how many days a week (0-7) during 
the last month they have struggled with six specified symptoms of insomnia. The scale can be 
used as a continuous measure or as a dichotomous/diagnostic measure. Higher scores indicate 
more symptoms of insomnia when BIS is used as a continuous measure. The diagnostic 
criteria of insomnia are met with a score of ≥3 on at least one of the first four items (night-
time symptoms) and a score of ≥3 on at least one of the last two items (daytime symptoms). 
Cronbach´s alpha of BIS was .58 at pre-treatment, .82 at post-treatment, and .85 at 18-month 
FU. 
The Brief Dysfunctional Beliefs and Attitudes Scale (DBAS-16)19 is a self-report 
questionnaire designed to identify various maladaptive sleep- and insomnia-related 
cognitions. Participants are given a list of 16 statements reflecting different beliefs and 
attitudes about sleep, and they are asked to indicate on a 10-point scale how much they agree 
with the statements. A high score indicates more maladaptive beliefs that are assumed to have 
a potential perpetuating effect on insomnia symptoms. The scale has proven adequate internal 
consistency both for clinical and research samples.19 Also, in the present study, internal 
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consistency was high, where Cronbach´s alphas for the DBAS-16 at the different assessment 
points were .81 at pre, .89 at post, and .89 at 18-month FU, respectively. 
Sleep diaries20  that were completed online were used to register subjective sleep data, 
where participants provided daily estimates of their sleep the previous night during the 
baseline assessment, post-treatment assessment, and at 18-month FU (10 days of diaries in a 
14-day window were required at each assessment point). Throughout the assessment periods, 
participants received automated daily reminders on e-mail to complete the sleep diary. The 
following measures were derived from the diary: Sleep onset latency (SOL), wake after sleep 
onset (WASO, time awake during the night), early morning awakening (EMA, time spent in 
bed after final wake-up), time in bed (TIB), total sleep time (TST), and sleep efficiency (SE, 
total sleep time as a percentage of time in bed). In the current study, the analyses were based 
on mean scores of the 10 days for each of the respective sleep diary parameters – in line with 
previous publications.7,8  
The Hospital Anxiety and Depression Scale (HADS) is a widely used measure of general 
psychological distress.21 The scale comprises 14 questions pertaining to non-vegetative 
symptoms of anxiety and depression. Each item is rated on a 0-4 Likert scale. A higher score 
indicates greater symptom severity. The HADS can be used to separately assess symptom 
severity of anxiety and depression. However, in the present study the subscales were 
combined into one general factor measuring psychological distress, adhering to previous 
studies that have demonstrated superior factor loadings on one general factor.22,23 Scores on 
the HADS using the general factor range between 0-56. The recommended cut-off point for 
identifying clinical cases of anxiety and depression is ≥8 on both subscales.21,22 Cronbach´s 
alphas at the different assessment points were .82 at pre, .83 at post, and .82 at 18-month FU.  
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Chalder Fatigue Questionnaire (CFQ)24 is a self-administered questionnaire used to 
measure the extent and severity of participants’ fatigue complaints. CFQ comprises 11 items 
addressing physical and psychological fatigue, and 2 items addressing the duration (from ‘less 
than one week’ through ‘six months or more’) and the frequency of fatigue complaints (i.e. 
how much of the time they feel fatigued; from ‘25% of the time’ through ‘all the time’). Each 
item is answered on a 4-point scale ranging from asymptomatic to maximum 
symptomatology. A composite score including all 13 items was used in the present study with 
scores ranging from 0 to 39. Reliability measures of CFQ have been high both in clinical 
samples25 as well as in the general population.26 CFQ was chosen as a measure of fatigue in 
the present study since a Norwegian validated version was available.26 In the present study, 
Cronbach´s alphas for CFQ at the different assessment points were .84 at pre, .85 at post, and 
.86 at 18-month FU. 
Statistics 
All analyses were performed using IBM© SPSS Statistics, version 23 (IBM SPSS 
Statistics, New York, USA). The long-term effects (18-month FU) of ICBTi were examined 
using linear mixed models for repeated-measures analysis, where all participants with 
baseline data were included in the analysis in line with the intention to treat principle. Two 
consecutive mixed model analyses were performed. In the first, baseline assessments were 
used as reference and compared to post-treatment and 18-month FU assessments; while in the 
second, post-treatment assessments were used as reference and compared to the 18-month FU 
assessments. Furthermore, we used independent samples t-tests and Chi-square test for 




No constraints were imposed on the covariance structure for repeated measures (type = 
unstructured). Mixed model analysis uses maximum likelihood estimation and can handle 
data that are missing at random (MAR) on dependent variables. Although there are no 
conclusive tests to prove the assumption of MAR, it is generally considered a more realistic 
assumption as compared to missing completely at random (MCAR). Under the assumption of 
MAR (missing at random), the estimates are still valid, and provide valuable information 
about the extent to which the changes from baseline to post-treatment are maintained at 18-
month FU.  
Effect sizes (Cohen’s d) were calculated in line with the recommendations of Carlson et 
al.27 and Morris28 and were based on the results from the mixed model analyses (estimated 
means and their standard errors). Effect size estimations were conducted in such a way that 
improvements always were reflected by positive effect sizes, whereas negative effect sizes 
consistently conveyed worsening. Effect sizes are shown in Table 1. Effect sizes are regarded 
as large (d = 0.8), moderate (d = 0.5), or small (d = 0.2) according to recognized guidelines.29 
Sample size calculation 
Previous studies on face-to-face CBTi have yielded between-group effect sizes (Cohen’s 
d) commonly in the range from 0.5 to 1.0 on important sleep diary outcomes (SOL, WASO, 
number of awakenings, EMA, TIB, TST, and SE) at post assessment, while the first study that 
was carried out on the ICBTi SHUTi program compared to a wait-list control yielded between 
group effect-sizes in the range of 0.4 (total sleep time) to 1.0 (sleep onset latency) on sleep 
diary-derived variables at post. The present study was originally powered to be able to detect 
a difference between ICBTi and a patient education group at post treatment of 0.45 (for 
greater description, see first paper from this clinical trial7). With a power of .80 at p=.05 (two-
tailed), the number of participants needed in each group in order to detect differences on the 
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sleep diary outcomes was estimated to be 79.30 The sample size was increased to account for 
an anticipated dropout rate of approximately 20%, and 205 participants with insomnia were 
finally included in the original study, where 95 of these were allocated to the ICBTi condition 
investigated in the present study. Furthermore, the present study has a repeated measures 
design using within-subject analyses only, which further strengthens the statistical power.  
RESULTS 
Sample characteristics 
The sample characteristics have been described previously7 and are therefore only briefly 
described here. Mean age of the 95 participants was 45.5 years (SD=12.6) upon enrollment, 
and most were female (64%) and married/cohabiting (64%). Mean years of education was 
16.3 (SD=3.2), which corresponds to a completed bachelor’s degree. Sixteen percent of the 
participants had been suffering from insomnia for 3-11 months, 58% for 1-10 years, and 26% 
for more than 10 years. Sixty-six (70%) of the 95 participants first enrolled in the study 
completed the 18-month FU assessment (Figure 1). No significant differences between 18-
month FU completers and those lost to follow-up were observed on the parameters described 
above. However, those lost to 18-month FU had a somewhat higher baseline ISI score 
(M=18.6, SD=4.5) than the FU completers (M=16.9, SD=3.3), t (93) = 1.83, p=.041 (two 
tailed). There were no significant differences between FU completers and dropouts on any of 
the other variables.  
The total number of individuals with clinical anxiety or depression identified with the 
HADS at baseline was 33 out of 95 (34.7%). Of these 33 participants, 78.8% completed the 
post-assessment and 72.7% completed the 18-month FU. Of the 62 participants who scored 
below the threshold for anxiety/depression at baseline, 82.3% completed the post-assessment 
and 67.7% completed the 18-month FU. Furthermore, we calculated the corresponding 
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assessment completion rates based on those who reported taking any form of medication for 
sleep problems (incl. z-hypnotics, antidepressants, antihistamines and melatonin) at baseline 
versus those who did not. In total, 23 of 95 participants (24.2%) used some form of sleep 
medication at baseline, of which 65.2% completed the post-assessment and 52.2% completed 
the 18-month FU. In comparison, of those who did not use any sleep medication at baseline, 
86.1% completed the post-assessment and 75.0% completed the 18-month FU. However, as 
pointed out in the previous paragraph, non-completers of the 18-month FU were not more 
likely (although close to significant) to use sleep medication at baseline compared to those 
who did not use medication, χ2(df = 1, n=95)=3.82, p=.051, phi=-.23. 
Baseline to post-treatment/18-month FU 
Table 1 presents a summary of the results from the linear mixed models. Results for the 
primary outcome measures of ISI and BIS showed large and significant improvements from 
baseline to post-treatment (ISI, p<.001; BIS, p<.001) and from baseline to 18-month FU 
assessment (ISI, p<.001; BIS, p<.001).  
On secondary sleep outcomes, significant improvements were observed across all sleep 
diary parameters from baseline: SOL (to post-treatment, p<.001; to 18-month FU, p<.001), 
WASO (to post-treatment, p<.001; to 18-month FU, p<.001), and EMA (to post-treatment, 
p<.001; to 18-month FU, p<.001) with moderate to large effect sizes. Baseline SE of 72% 
(SD=12.0) improved to 87% (SD=5.8) at post-treatment (p<.001), and 84% (SD=10.9) at 18-
month FU (p<.001) both with large effect sizes. Mean TST increased from 5.6 hours (SD=1.4) 
at baseline to 6.1 hours (SD=0.9) at post-treatment (p<.001), and 6.3 hours (SD=1.0) at 18-
month FU (p<.001), both with small to moderate effect sizes.  
Participants scored significantly lower on the DBAS-16 at post-treatment (p<.001) and at 
18 month FU (p<.001) relative to baseline, both with large effect sizes. Psychological distress 
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(HADS) improved significantly from baseline to post-treatment (p<.001) and to 18-month FU 
(p<.001) with moderate effect sizes. The fatigue scores showed large effect size 
improvements from baseline to post-treatment (p<.001) and to 18-month FU (p<.001). 
Post-treatment to 18-month FU 
Overall, the improvements obtained at post-treatment were maintained at 18-month FU 
(Table 1). We found no significant changes on the ISI or the BIS from post-treatment to 18-
month FU. Patient scores on DBAS-16 further improved from post-treatment to 18-month FU 
(p=.030) with a small effect size. As for the sleep diary measures SOL (p=.035), WASO 
(p=.012), and EMA (p=.010), small but significant setbacks were observed. Significant 
setbacks were also observed in terms of SE, where mean SE dropped from 87% (SD=8.4) at 
post-treatment to 84% (SD=10.7) at 18-month FU (p=.002). TST significantly increased from 
post-treatment to 18-month FU (p=.025), from 6.1 hours (SD=0.9) to 6.3 hours (SD=1.0), 
respectively. The improvements observed on the measure of psychological distress (HADS) 
after treatment completion remained stable at 18-month FU. In terms of fatigue (CFQ), a 
small setback was observed from post-treatment to 18-month FU (p=.047). 
Insomnia remitters and responders 
Baseline data indicated a mean ISI score of 17.4 (SD=3.7) (Table 2), which is within the 
range of moderate to severe clinical insomnia. At baseline, all participants reported an ISI 
score of 8 points or more, referring to the threshold for remission used in previous studies.15 
At 18-month FU, 37% reported an ISI score of less than 8 points, indicating that they were in 
remission. A decrease of ≥8 ISI points has been suggested as an indicator of a responder to 
the treatment,15 and, at 18-month FU, 46% fulfilled this criterion. All participants meet the 




The purpose of the present study was to investigate the extent to which the observed 
improvements from baseline to after the intervention period are also maintained at 18 months 
after the intervention period. The study sample comprised the experimental group of a 
previously published RCT comparing ICBTi to web-based patient education, where 
superiority of ICBTi over patient education was demonstrated short-term.7,8 Findings in the 
present study indicate that the effects for the ICBTi group overall were good at 18-month FU 
evaluation, reflected by effect sizes ranging from 0.5 (SOL) to 2.0 (ISI) on all outcome 
measures. Compared to studies with shorter FU time, the overall effects in the present study 
appeared slightly higher than those reported in recent meta-analyses on self-help interventions 
for insomnia,1,31 and are comparable in magnitude to those found in similar studies on fully 
automated ICBTi3,4,32 and in-person delivered CBTi.33  
It is particularly important to establish the long-term effects of unguided self-help 
interventions because of the potential for cost-effective dissemination on a population level. 
Current evidence suggests that interventions including elements of therapist support are 
somewhat more effective than those without.1 However, we found that large and sustained 
effects also could be achieved using fully automated ICBTi. This is especially notable as only 
those with severe psychiatric comorbidity were excluded, whereas disorders like mild to 
moderate depression and anxiety disorders were included. The present report adds to the list 
of studies showing promising effects of treatments that can replicate effects of in-person 
CBTi, both in terms of individualizing treatment and making the therapeutic concepts 
accessible for participants through interactive educational tools.3,4,32,34,35 
On most parameters, participants showed the greatest improvement immediately after 
completing the treatment. If small setbacks occurred, they were observed at 18-month FU. 
Still, the setbacks from post-treatment to 18-month FU on sleep diary measures appeared 
negligible considering that mean SOL, WASO, and EMA still remained below the clinically 
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meaningful threshold of 30 minutes at 18-month FU,36 and SE decreased from 87% after the 
intervention period to 84% at 18-month FU, which is only marginally below the clinical 
threshold of 85%.37 Importantly, a significant improvement on total sleep time (TST) from 
treatment completion to 18-month FU was observed. The sleep diary data results are 
interesting as the recent meta-analysis by Zachariae et al.1 render the long-term effects of 
ICBTi on sleep diary outcomes somewhat elusive, particularly after adjusting for possible 
publication bias. 
Increase in TST from treatment termination to follow-up is a phenomenon also shown in 
studies on in-person delivered CBTi; where TST typically remain unchanged or even reduced 
during the initial intervention, but increases at FU evaluation.37-39 Many participants may at 
post-treatment still be adhering to a limited time in bed (cf. sleep restriction), and spend the 
following weeks or months reaching a sleep duration that meets their needs. A transient 
feature of sleep restriction is consequently an elevated sleep drive that may give rise to an 
artificially high SE (and correspondingly low SOL, WASO and EMA), which might be 
expected to ebb somewhat and then to stabilize as TST increases to match the participants 
sleep need. However, the finding that fewer participants were in remission at FU compared to 
post-treatment as defined by the ISI or BIS suggests that a few participants experienced 
relapse of sleep problems (Table 2). In addition, we found a small increase in fatigue scores 
from treatment completion to 18-month FU. These findings are in contrast to those reported 
from a three-year follow-up study comparing guided with unguided ICBTi, reporting that 
more participants in both conditions were in remission at FU as compared to post-treatment.40 
Similarly, the recent study by Ritterband et al.4 assessing the effects of a fully automated 
ICBTi also indicated that more people were in remission at 1-year FU, as compared to 6-
month FU and post-treatment. 
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Even though there was a small but significant setback after the intervention period (post-
treatment to 18-month FU) in levels of fatigue, the effect size improvements from baseline to 
18-month FU evaluation remained large. Thus, we overall conclude that the beneficial effects 
of the treatment on fatigue complaints were substantial and lasting. These findings are in line 
with previous studies demonstrating short-term effects,34,41 but the current study extends these 
results to evidence of sustained effects beyond treatment completion. Furthermore, on general 
psychological distress, we demonstrated moderate effect size improvements from baseline to 
post-assessment and to 18-month FU, and there was no significant change between post-
assessment and FU evaluation. This is in line with prior results that show treatment targeting 
insomnia reduces psychological symptoms, both when the treatment is delivered in person42 
and when delivered online.6,34,35 One study found that unguided ICBTi compared to a control 
group reduced symptoms of anxiety and depression with moderate between group effect sizes, 
where the effects were maintained and appeared unabated to a 18-month FU evaluation.6 The 
fact that only 19% of participants completed the 18-month assessment in that study makes the 
results on the long-term effects somewhat uncertain. However, 70% of the participants in the 
present study completed the 18-month FU, and our observations confirm that the effects 
appear maintained up to 18-months after the intervention period. A cautionary note when 
interpreting these results is that only 34% of the participants were in the clinical range of 
anxiety/depression at baseline. These effects are nevertheless noteworthy considering that the 
ICBTi treatment does not directly address anxiety and depressive symptoms and the 
intervention does not propound any booster sessions. These findings suggest that the presence 
of symptoms of mild to moderate psychological distress and fatigue should not be a pretext to 
postpone insomnia treatment, which delivered online might be a valuable supplement to 




It should be noted that the 18-month FU evaluation in the current study did not include a 
control group, which precludes firm causal inferences about the long-term effects of ICBTi 
due to lack of control for several threats to internal validity.43 Participants typically 
experience a peak in symptoms upon seeking treatment, where it is reasonable to expect a 
regression towards mean with passage of time. However, chronic insomnia emerges as a 
persistent disorder where nearly 70% will still have the disorder a year later, and 50% three 
years later when left untreated.44 Still, we know little about the prognosis of untreated 
insomnia. Participants in the present study had long histories of chronic insomnia, which 
makes spontaneous recovery of the magnitude we observed an unlikely explanation. 
Participants with a higher ISI score at baseline were more likely not to complete the 18 month 
FU, and those who used sleep medication at baseline had a tendency (close to significant) 
towards not completing the 18 month FU, which potentially can lead to a bias in the present 
study. It is possible that missing data at FU is partly MNAR. This can imply a risk of under- 
or overestimation of the true change. A sensitivity analysis is recommended in order to check 
how MNAR may impact change estimates. This was nevertheless not carried out due to the 
relatively low N in the current sample. One limitation of the present study is that other sleep 
disorders were only assessed through a short online screening questionnaire and a telephone 
interview, and no objective measures or standardized assessments were used to rule out other 
sleep disorders. It is also a limitation that no objective sleep measure (e.g. actigraphy or 
polysomnography) was used as outcome measure. Another limitation pertains to the low 
internal consistency of the baseline scores of the ISI and the BIS; however, this is most likely 
a reflection of the restricted range of scores at this measurement time. It should also be noted 
that the measure of fatigue used in this study (the CFQ) is not among the consensus 
recommendations for assessments in insomnia.45 CFQ has nevertheless shown good 
psychometric properties with high reliability also in clinical samples.25 Most participants were 
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recruited after various media appearances of the authors and may thus represent a self-
selected group of resourceful and especially motivated individuals. In line with this, the 
average education level in the current sample was high; 76.2% had completed at least one 
year of higher education (university/university college level), compared to 32.2% in the 
Norwegian population as a whole (Statistics Norway). As such, we cannot know whether the 
observed effects in the present study are transferable to participants referred from general 
practice. However, this is a limitation that pertains to most studies on fully automated ICBTi 
(e.g.3,4,32,34).   
Conclusion 
Overall, our results add to the small, but growing evidence that the effects of unguided 
ICBTi are of a substantial magnitude, comparable to in-person CBTi and well maintained 
long-term.2,40 The overall effects seem largest immediately after the intervention period and 
appear to become somewhat reduced at FU evaluations. It should be noted that booster 
sessions were not offered in the present study, and we might have seen even better results at 
18-month FU if this had been offered. Further work on the long-term effects of ICBTi should 
evaluate the effects of treatment in study designs that also include control groups. Also, future 
studies should incorporate a wider range of long-term functional outcome measures that go 
beyond sleep and symptoms of distress, such as sick leave, medication use, use of health care 
services, and other measures of general health. Studies should also aim to evaluate the 
effectiveness of ICBTi in clinical settings, both in comparison to in-person delivered CBTi 
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Figure 1. Consort diagram and participant flow (note that only the results from 18-month 




Online screening questionnaire 
(n=1538) 
Excluded (n=1231) 
♦   Not insomnia (n=130) 
♦   Night work (n=51) 
♦   Other health complaint  (n=437) 
♦   Other reasons/withdrew (n=613) 
Post-assessment                                          
77 completed the questionnaires                     
68 completed the diaries                            
Randomized to Internet-delivered CBTi                     
95 got access to SHUTi for 9 weeks 
Post-assessment                                          
65 completed the questionnaires                     
51 completed the diaries                            
(Note that the results from the RCT is reported 
in previous publications.7,8) 
Randomized to sleep hygiene advice         
86 got access to web-site with sleep hygiene 
advice for 9 weeks. 
Baseline assessment               
181 completed the questionnaires    
181 completed the diaries 
Enrollment 
Screening interview 
307 interview by phone 
Excluded (n=102)  
♦   Not insomnia, other sleep disorder, 
currently under psychological 
treatment, withdrew. 
18 month FU assessment                               
66 completed the questionnaires                             
62 completed the diaries 
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Table 2. Insomnia remitters and responders (N=95). 




18-month FU  
(n=67) 
ISI mean (SD) 17.4 (3.7) 8.8 (5.8) 9.8 (7.3) 
ISI remitters (cut off <8) NA 48% 37% 
ISI responders (reduction of ≥8)  56% 46% 
BIS mean (SD) 25.9 (7.1) 12.5 (8.3) 13.6 (9.8) 
BIS remitters NA 51% 53% 
Note. ISI = Insomnia severity index; BIS = Bergen insomnia scale. ISI remitters are participants who 
attain an ISI score of less than 8 points15 at the different assessments. ISI responders are participants 
who achieve a reduction of ≥8 ISI points relative to baseline assessment. BIS remitters are participants 








Table 1. Results from linear mixed models (N = 95). 
  Mean SE 95% CI d 95% CI  d 95% CI  











Sleep variables        
Insomnia Severity Index (ISI)        
  Baseline  17.4 0.4 16.6 to 18.2     
  Post treatment 8.8 0.6 7.6 to 10.0 2.30*** 1.90 to 2.70   
  18-month FU 9.8 0.7 8.3 to 11.3 2.04*** 1.66 to 2.42  -0.17 -0.01 to 0.35 
Bergen Insomnia Scale (BIS)        
  Baseline  25.9 0.7 24.4 to 27.3     
  Post treatment 15.0 0.9 13.2 to 16.7 1.53*** 1.24 to 1.82   
  18-month FU 14.2 1.2 11.8 to 16.6 1.64*** 1.30 to 1.98 0.09 -0.12 to 0.30 
DBAS-16        
  Baseline  5.0 0.2 4.7 to 5.3     
  Post treatment 3.3 0.2 2.9 to 3.7 0.87*** 0.65 to 1.09   
  18-month FU 2.9 0.2 2.5 to 3.3 1.08*** 0.83 to 1.13 0.21* 0.03 to 0.39 
Sleep onset latency (min)        
  Baseline  48.5 4.3 40.0 to 57.0     
  Post treatment 21.1 1.9 17.4 to 24.8 0.65*** 0.45 to 0.85   
  18-month FU 26.8 3.0 20.8 to 32.9 0.52*** 0.33 to 0.71  -0.31* -0.51 to -0.11 
Wake after sleep onset (min)        
  Baseline  44.6 3.3 38.1 to 51.2     
  Post treatment 18.8 2.1 14.5 to 23.0 0.81*** 0.58 to 1.04   
  18-month FU 26.3 2.8 20.7 to 31.9 0.57*** 0.32 to 0.82  -0.36** -0.58 to -0.14 
Early morning awakening (min)       
  Baseline  38.4 2.8 32.9 to 43.9     
  Post treatment 15.9 1.9 12.2 to 19.6 0.84*** 0.60 to 1.08   
  18-month FU 20.2 2.1 16.0 to 24.5 0.67*** 0.45 to 0.89  -0.24* -0.40 to -0.08 
Time in bed (hours)        
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  Baseline  7.8 0.1 7.6 to 8.0     
  Post treatment 7.0 0.1 6.9 to 7.2 -0.79*** -1.00 to -0.58   
  18-month FU 7.5 0.1 7.3 to 7.7 -0.28** -0.47 to -0.09  0.53*** 0.31 to 0.75 
Total sleep time (hours)        
  Baseline  5.6 0.1 5.4 to 5.9     
  Post treatment 6.1 0.1 5.9 to 6.3  0.44*** 0.29 to 0.59   
  18-month FU 6.3 0.1 6.1 to 6.5  0.62*** 0.41 to 0.83  0.22* 0.02 to 0.42 
Sleep efficiency (%)        
  Baseline  72.1 1.2 69.7 to 74.5     
  Post treatment 86.8 0.9 85.1 to 88.5  1.23*** 0.97 to 1.49   
  18-month FU 84.1 1.1 81.8 to 86.3  1.00*** 0.75 to 1.25 -0.33** -0.50 to -0.16 
Daytime functioning        
HADS total score        
  Baseline  9.7 0.6 8.6 to 10.8     
  Post treatment 6.8 0.3 5.7 to 7.9 0.54*** 0.37 to 0.71   
  18-month FU 6.9 0.6 5.7 to 8.1 0.51*** 0.29 to 0.73 -0.03 -0.18 to 0.24 
Chalder Fatigue Questionnaire        
  Baseline  18.9 0.6 17.8 to 20.0     
  Post treatment 12.9 0.6 11.7 to 14.1 1.12*** 0.85 to 1.39   
  18-month FU 14.4 0.7 13.0 to 15.7 0.85*** 0.59 to 1.11  -0.25* -0.47 to -0.03 
Note. Effect sizes are specified relative to baseline and to post treatment. Effect size estimations were conducted in such a way 
that improvements always were reflected by positive effect sizes, whereas negative effect sizes consistently conveyed worsening. 
* p<,05; ** p<,01; *** p<,001 
 
